お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
921275

ウェアラブルインジェクター市場 - 成長、傾向、予測

Wearable Injectors Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.99円
ウェアラブルインジェクター市場 - 成長、傾向、予測
出版日: 2020年06月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のウェアラブルインジェクター市場は、2020年から2025年にかけて10.4%のCAGRで拡大すると予測されています。慢性疾患の有病率の増加、技術の進歩、設計開発、針刺し損傷に関連する危険性、および単純な注射器による薬物送達の制限に対する懸念の高まり等が市場の成長の要因です。

当レポートでは、ウェアラブルインジェクターの世界市場を調査し、市場の概要、タイプ、エンドユーザー、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています 。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概要
  • 成長要因
  • 抑制要因
  • ファイブフォース分析
    • 新規参入の脅威
    • 消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内での競争

第5章 市場セグメンテーション

  • タイプ別
    • オンボディ型
    • オフボディ型
  • 療法別
    • 腫瘍学
    • 自己免疫疾患
    • 糖尿病
    • 循環器疾患
    • その他
  • エンドユーザー別
    • 病院・診療所
    • ホームケア
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Amgen
    • Becton, Dickinson and Company
    • Dexcom, Inc.
    • Enable Injections
    • Insulet Corporation
    • Sensile Medical
    • Tandem Diabetes Care, Inc.
    • Ypsomed

第7章 市場機会および将来動向

目次
Product Code: 67123

Certain factors that are driving the market growth include the growing prevalence of chronic diseases, technological advancements and design development, increasing concern over the hazards related to needlestick injuries, and limitations of drug delivery through a simple syringe.

With wearable injectors costing on average between USD 20 and USD 35 per unit, they can reduce the total healthcare costs, compared to the home administration of IV infusion drugs, by allowing patients to self-inject a therapy without the need of any kind of medical supervision or additional equipment. Enabling a patient to self-administer during the course of their normal daily lives, such as at home or work also creates a significant potential to improve rates of therapy compliance.

The ability for a patient to conveniently wear a compact, disposable device on the body during the subcutaneous injection of a large dose volume may also minimize the need for less-understood technologies in development that seek to temporarily change the subcutaneous space to enable rapid injections of large dose therapies. Hence all these factors are expected to contribute to the market growth over the forecast period.

Key Market Trends

Oncology is Expected to Hold Significant Market Share in the Therapy Segment

Wearable injectors are observing a huge increase in its adoption across the healthcare industry as cancer patients have realized the essential benefits such as a reduction in disease progression and pain. The On-body Injector is usually placed on the stomach or the back of the arm. It is applied by a nurse, usually on the last day of each chemotherapy cycle. Hence, the rise in the prevalence of cancer and cardiac ailments is one of the primary drivers for the market.

The cancer rates could increase by 50%, i.e. to 15 million new cases by the year 2020, as per the World Cancer Report (published in April 2018). It also states that healthy lifestyles and various public health initiatives by governments and health practitioners could originate this trend, and prevent as many as one-third of cancer cases, worldwide.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the National Cancer Institute (NCI), in 2016, 1.6 million people were suffering from cancer, and around 0.5 million people died from cancer. This figure indicates that the prevalence of cancer is rapidly increasing in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colon and rectum cancer, bladder cancer, and skin cancer.

Also according to the American Diabetes Association, diabetes has a greater health impact on Americans than heart disease, substance use disorder or COPD, with 30.3 million Americans diagnosed with the illness and many more who are at risk for developing it. The prevalence of these diseases are expected to drive the growth in demand for wearable injectors all across the region.

Competitive Landscape

The global wearable injectors market is moderately competitive and consists of a number of major players. Companies like Amgen, Becton, Dickinson and Company, Dexcom, Inc., Enable Injections, Insulet Corporation, Sensile Medical , Tandem Diabetes Care, Inc., Ypsomed, among others, hold the substantial market share in the wearable Injectors market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Chronic Diseases
    • 4.2.2 Technological Advancements and Design Development
    • 4.2.3 Increasing Concern over the Hazards and Limitations Related to Needlestick
  • 4.3 Market Restraints
    • 4.3.1 Preference for Alternative Drug Delivery Modes
    • 4.3.2 Unfavorable Reimbursement Structure in Developing Countries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 On-Body Injectors
    • 5.1.2 Off-Body Injectors
  • 5.2 By Therapy
    • 5.2.1 Oncology
    • 5.2.2 Autoimmune Disease
    • 5.2.3 Diabetes
    • 5.2.4 Cardiovascular Disease
    • 5.2.5 Others
  • 5.3 By End User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Home Care
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Dexcom, Inc.
    • 6.1.4 Enable Injections
    • 6.1.5 Insulet Corporation
    • 6.1.6 Sensile Medical
    • 6.1.7 Tandem Diabetes Care, Inc.
    • 6.1.8 Ypsomed

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.